In conclusion, this study found for the first time that serous ovarian carcinomas with increased KRT5 and KRT6 mRNA expression, as well as increased K5 or K5/6 immunostaining have an increased risk of disease relapse. The gene discussed is KRT5; the disease is ovarian serous carcinoma.